These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 31333236)

  • 1. [Successful treatment of gangrenous pyoderma with methotrexate in a patient withCrohn's disease].
    Duarte-Chang C; Visuetti S
    Rev Gastroenterol Peru; 2019; 39(2):175-177. PubMed ID: 31333236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutrophilic dermatoses: a review of current treatment options.
    Cohen PR
    Am J Clin Dermatol; 2009; 10(5):301-12. PubMed ID: 19658442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous cyclosporine therapy in the treatment of pyoderma gangrenosum secondary to Crohn's disease.
    Carp JM; Onuma E; Das K; Gottlieb AB
    Cutis; 1997 Sep; 60(3):135-8. PubMed ID: 9314617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The role of biologic therapy in the treatment of extraintestinal manifestations and complications of inflammatory bowel disease].
    Kujundzić M
    Acta Med Croatica; 2013 Apr; 67(2):195-201. PubMed ID: 24471303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Certolizumab pegol - A new therapeutic option for refractory disseminated pyoderma gangrenosum associated with Crohn's disease.
    Hurabielle C; Schneider P; Baudry C; Bagot M; Allez M; Viguier M
    J Dermatolog Treat; 2016; 27(1):67-9. PubMed ID: 25909366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extraintestinal manifestations of Crohn's disease.
    Juillerat P; Mottet C; Froehlich F; Felley C; Vader JP; Burnand B; Gonvers JJ; Michetti P
    Digestion; 2005; 71(1):31-6. PubMed ID: 15711047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case report of successful treatment of pyoderma gangrenosum in a patient with autoimmune hepatitis, and review of the literature.
    Androutsakos T; Stamopoulos P; Aroni K; Hatzis G
    BMC Gastroenterol; 2015 Oct; 15():149. PubMed ID: 26502871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case Report: Triple Combination Therapy for Recalcitrant Perineal Pyoderma Gangrenosum.
    Shaath TS; Om A; Wolfe CM; Cohen GF
    J Drugs Dermatol; 2019 Mar; 18(3):307-310. PubMed ID: 31020825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extraintestinal manifestations of Crohn's disease.
    Juillerat P; Mottet C; Pittet V; Froehlich F; Felley C; Gonvers JJ; Vader JP; Michetti P
    Digestion; 2007; 76(2):141-8. PubMed ID: 18239406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyoderma gangrenosum and myelodysplastic syndrome.
    Litvak D; Kirsner RS; Pakdaman NN; Federman DG
    South Med J; 2000 Sep; 93(9):923-5. PubMed ID: 11005358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pyoderma gangrenosum as a first presentation of inflammatory bowel disease.
    Shahid S; Myszor M; De Silva A
    BMJ Case Rep; 2014 Nov; 2014():. PubMed ID: 25385558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutaneous manifestations in inflammatory bowel disease.
    Tromm A; May D; Almus E; Voigt E; Greving I; Schwegler U; Griga T
    Z Gastroenterol; 2001 Feb; 39(2):137-44. PubMed ID: 11253504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive factors for erythema nodosum and pyoderma gangrenosum in inflammatory bowel disease.
    Ampuero J; Rojas-Feria M; Castro-Fernández M; Cano C; Romero-Gómez M
    J Gastroenterol Hepatol; 2014 Feb; 29(2):291-5. PubMed ID: 23927379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic pyoderma gangrenosum responding to infliximab and adalimumab.
    Hubbard VG; Friedmann AC; Goldsmith P
    Br J Dermatol; 2005 May; 152(5):1059-61. PubMed ID: 15888172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of infliximab on extraintestinal manifestations of Crohn's disease.
    Kaufman I; Caspi D; Yeshurun D; Dotan I; Yaron M; Elkayam O
    Rheumatol Int; 2005 Aug; 25(6):406-10. PubMed ID: 15309501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Extensive ulcerations in children: The difficulty diagnosing pyoderma gangrenosum].
    Ramli I; Rachadi H; Amarouch H; Rimani M; Senouci K; Benzekri L; Hassam B
    Arch Pediatr; 2015 Jul; 22(7):753-5. PubMed ID: 26047747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peristomal pyoderma gangrenosum and inflammatory bowel disease.
    Cairns BA; Herbst CA; Sartor BR; Briggaman RA; Koruda MJ
    Arch Surg; 1994 Jul; 129(7):769-72. PubMed ID: 7912923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of pyoderma gangrenosum with infliximab in Crohn's disease.
    Sapienza MS; Cohen S; Dimarino AJ
    Dig Dis Sci; 2004 Sep; 49(9):1454-7. PubMed ID: 15481318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Refractory pyoderma gangrenosum of the orbit and the lacrimal sac.
    Cordero-Coma M; Pérez-Moreiras JV; Toribio A; Alonso-Orcajo N; Calleja S; Franco M; Ruiz de Morales JG
    Orbit; 2012 Aug; 31(4):249-51. PubMed ID: 22571540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.